Sonelokimab Shows Sustained One-Year Benefits in Hidradenitis Suppurativa, With Encouraging Early Results in Adolescents

As reported on Healio, new phase 3 data suggest that sonelokimab may offer durable disease control for patients with moderate to severe hidradenitis suppurativa (HS), with more than two-thirds of…

Continue Reading Sonelokimab Shows Sustained One-Year Benefits in Hidradenitis Suppurativa, With Encouraging Early Results in Adolescents

ICYMI: Make HStory Platform Offers Hidradenitis Suppurativa Education and Community Support

Editor's Note: This article was originally published by Patient Worthy on 6/7/24, and is being republished due to our ongoing efforts to raise awareness of Hidradenitis Suppurativa (HS). The importance…

Continue Reading ICYMI: Make HStory Platform Offers Hidradenitis Suppurativa Education and Community Support
The Latest Webinar from NORD Showcases the Rare Disease Patient Experience
source: pixabay.com

The Latest Webinar from NORD Showcases the Rare Disease Patient Experience

On April 28, 2022, the National Organization for Rare Disorders (NORD) and the Rare Disease Diversity Coalition hosted a webinar program titled "Walk in Our Shoes: The Experience of Rare…

Continue Reading The Latest Webinar from NORD Showcases the Rare Disease Patient Experience